Michael Liptay to Lymphatic Metastasis
This is a "connection" page, showing publications Michael Liptay has written about Lymphatic Metastasis.
Connection Strength
0.874
-
Status of sentinel lymph node mapping in non-small cell lung cancer. Cancer J. 2015 Jan-Feb; 21(1):17-20.
Score: 0.126
-
Enhancement of a multianalyte serum biomarker panel to identify lymph node metastases in non-small cell lung cancer with circulating autoantibody biomarkers. Int J Cancer. 2011 Jul 01; 129(1):133-42.
Score: 0.094
-
Pneumonectomy after chemoradiation therapy for non-small cell lung cancer: does "side" really matter? Ann Thorac Surg. 2009 Sep; 88(3):937-43; discussion 944.
Score: 0.087
-
Establishment of a multi-analyte serum biomarker panel to identify lymph node metastases in non-small cell lung cancer. J Thorac Oncol. 2009 Mar; 4(3):338-47.
Score: 0.084
-
Intraoperative sentinel node mapping with technitium-99 in lung cancer: results of CALGB 140203 multicenter phase II trial. J Thorac Oncol. 2009 Feb; 4(2):198-202.
Score: 0.084
-
Sentinel node mapping in lung cancer: introduction. Semin Thorac Cardiovasc Surg. 2009; 21(4):297.
Score: 0.083
-
Invited commentary. Ann Thorac Surg. 2008 Aug; 86(2):395.
Score: 0.081
-
Metastatic breast cancer and lung cancer within the same lymph node. Int J Surg Pathol. 2007 Apr; 15(2):169.
Score: 0.074
-
In vivo sentinel lymph node mapping in lung cancer. Ann Surg Oncol. 2005 Feb; 12(2):102-3.
Score: 0.063
-
Sentinel lymph node mapping in lung cancer. Cancer Treat Res. 2005; 127:141-50.
Score: 0.063
-
Development of a serum biomarker panel predicting recurrence in stage I non-small cell lung cancer patients. J Thorac Cardiovasc Surg. 2012 Dec; 144(6):1344-50; discussion 1350-1.
Score: 0.027
-
An historical perspective of multi-modality treatment for resectable non-small cell lung cancer. Lung Cancer. 1995 Jun; 12 Suppl 2:S17-32.
Score: 0.008